NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
10
11
2023
accepted:
25
03
2024
revised:
27
02
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
30
6
2024
Statut:
aheadofprint
Résumé
Proinflammatory cytokines and chemokines play a crucial role in regulating the inflammatory response, which is essential for the proper functioning of our immune system. When infections or threats to the body's defense mechanisms are detected, the innate immune system takes the lead. However, an excessive inflammatory response can lead to the production of high concentrations of cytotoxic molecules, resulting in tissue damage. Inflammasomes are significant contributors to innate immunity, and one of the most extensively studied inflammasome complexes is NOD-like receptor 3 (NLRP3). NLRP3 has a wide range of recognition mechanisms that streamline immune activation and eliminate pathogens. These cytosolic multiprotein complexes are composed of effector, adaptor, and sensor proteins, which are crucial for identifying intracellular bacterial breakdown products and initiating an innate immune cascade. To understand the diverse behavior of NLRP3 activation and its significance in the development of lifestyle-related diseases, one must delve into the study of the immune response and apoptosis mediated by the release of proinflammatory cytokines. In this review, we briefly explore the immune response in the context of lifestyle associated disorders such as obesity, hyperlipidemia, diabetes, chronic respiratory disease, oral disease, and cardiovascular disease.
Identifiants
pubmed: 38945951
doi: 10.1038/s12276-024-01261-8
pii: 10.1038/s12276-024-01261-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Health and Welfare (Ministry of Health, Welfare and Family Affairs)
ID : HN21C1058
Organisme : National Research Foundation of Korea (NRF)
ID : 2022M3A9G1014520
Organisme : National Research Foundation of Korea (NRF)
ID : 2023R1A2C2003034
Organisme : National Research Foundation of Korea (NRF)
ID : 2019M3D1A1078940
Organisme : National Research Foundation of Korea (NRF)
ID : 2019R1A6A1A11051471
Informations de copyright
© 2024. The Author(s).
Références
Saxena, M. & Yeretssian, G. NOD-like receptors: master regulators of inflammation and cancer. Front. Immunol. 5, 327 (2014).
pubmed: 25071785
pmcid: 4095565
doi: 10.3389/fimmu.2014.00327
Kufer, T. A. & Sansonetti, P. J. NLR functions beyond pathogen recognition. Nat. Immunol. 12, 121–128 (2011).
pubmed: 21245903
doi: 10.1038/ni.1985
Jo, E.-K., Kim, J. K., Shin, D.-M. & Sasakawa, C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol. Immunol. 13, 148–159 (2016).
pubmed: 26549800
doi: 10.1038/cmi.2015.95
Voet, S., Srinivasan, S., Lamkanfi, M. & van Loo, G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol. Med. 11, e10248 (2019).
pubmed: 31015277
pmcid: 6554670
doi: 10.15252/emmm.201810248
Olcum, M., Tastan, B., Ercan, I., Eltutan, I. B. & Genc, S. Inhibitory effects of phytochemicals on NLRP3 inflammasome activation: a review. Phytomedicine 75, 153238 (2020).
pubmed: 32507349
doi: 10.1016/j.phymed.2020.153238
Zheng, D., Liwinski, T. & Elinav, E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 6, 36 (2020).
pubmed: 32550001
pmcid: 7280307
doi: 10.1038/s41421-020-0167-x
Py, B. F., Kim, M.-S., Vakifahmetoglu-Norberg, H. & Yuan, J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49, 331–338 (2013).
pubmed: 23246432
doi: 10.1016/j.molcel.2012.11.009
Han, S. et al. Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase. J. Biol. Chem. 290, 18124–18133 (2015).
pubmed: 26037928
pmcid: 4505057
doi: 10.1074/jbc.M115.645549
Song, H. et al. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3. Nat. Commun. 7, 13727 (2016).
pubmed: 27929086
pmcid: 5155141
doi: 10.1038/ncomms13727
Yan, Y. et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160, 62–73 (2015).
pubmed: 25594175
doi: 10.1016/j.cell.2014.11.047
Song, N. et al. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol. Cell 68, 185–197.e6 (2017).
pubmed: 28943315
doi: 10.1016/j.molcel.2017.08.017
Zhang, Z. et al. Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J. Exp. Med. 214, 2671–2693 (2017).
pubmed: 28716882
pmcid: 5584123
doi: 10.1084/jem.20162040
Spalinger, M. R. et al. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J. Clin. Invest 126, 1783–1800 (2016).
pubmed: 27043286
pmcid: 4855944
doi: 10.1172/JCI83669
Stutz, A. et al. NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain. J. Exp. Med. 214, 1725–1736 (2017).
pubmed: 28465465
pmcid: 5460996
doi: 10.1084/jem.20160933
Arioz, B. I., Tarakcioglu, E., Olcum, M. & Genc, S. The role of melatonin on NLRP3 inflammasome activation in diseases. Antioxidants (Basel) 10, 1020 (2021).
pubmed: 34202842
doi: 10.3390/antiox10071020
Cao, S. S. & Kaufman, R. J. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid. Redox Signal 21, 396–413 (2014).
pubmed: 24702237
pmcid: 4076992
doi: 10.1089/ars.2014.5851
Elliott, E. I. & Sutterwala, F. S. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol. Rev. 265, 35–52 (2015).
pubmed: 25879282
pmcid: 4400874
doi: 10.1111/imr.12286
Yang, Y., Wang, H., Kouadir, M., Song, H. & Shi, F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 10, 128 (2019).
pubmed: 30755589
pmcid: 6372664
doi: 10.1038/s41419-019-1413-8
Zhou, Y. et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol. Neurodegener. 11, 28 (2016).
pubmed: 27084336
pmcid: 4833896
doi: 10.1186/s13024-016-0094-3
Wang, Z. et al. LncRNA MIAT downregulates IL-1β, TNF-ɑ to suppress macrophage inflammation but is suppressed by ATP-induced NLRP3 inflammasome activation. Cell Cycle 20, 194–203 (2021).
pubmed: 33459112
pmcid: 7889136
doi: 10.1080/15384101.2020.1867788
Brocker, C. N. et al. Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nat. Commun. 11, 5847 (2020).
pubmed: 33203882
pmcid: 7673042
doi: 10.1038/s41467-020-19554-7
Lin, Y. et al. Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ameliorate nonalcoholic steatohepatitis in mice. Theranostics 11, 426–444 (2021).
pubmed: 33391484
pmcid: 7681083
doi: 10.7150/thno.50281
Carpentier, S. J. et al. The signaling adaptor BCAP inhibits NLRP3 and NLRC4 inflammasome activation in macrophages through interactions with Flightless-1. Sci. Signal 12, eaau0615 (2019).
pubmed: 31088976
pmcid: 6604799
doi: 10.1126/scisignal.aau0615
de Almeida, L. et al. The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease. Immunity 43, 264–276 (2015).
pubmed: 26275995
pmcid: 4666005
doi: 10.1016/j.immuni.2015.07.018
Ratsimandresy, R. A. et al. The PYRIN domain-only protein POP2 inhibits inflammasome priming and activation. Nat. Commun. 8, 15556 (2017).
pubmed: 28580931
pmcid: 5465353
doi: 10.1038/ncomms15556
Hu, Y. et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J. Immunol. 185, 7699–7705 (2010).
pubmed: 21048113
doi: 10.4049/jimmunol.1001099
Martine, P. et al. HSP70 is a negative regulator of NLRP3 inflammasome activation. Cell Death Dis. 10, 256 (2019).
pubmed: 30874540
pmcid: 6420651
doi: 10.1038/s41419-019-1491-7
Eren, E., Berber, M. & Özören, N. NLRC3 protein inhibits inflammation by disrupting NALP3 inflammasome assembly via competition with the adaptor protein ASC for pro-caspase-1 binding. J. Biol. Chem. 292, 12691–12701 (2017).
pubmed: 28584053
pmcid: 5535042
doi: 10.1074/jbc.M116.769695
Pirzada, R. H., Javaid, N. & Choi, S. The roles of the NLRP3 inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions. Genes (Basel) 11, 131 (2020).
pubmed: 32012695
doi: 10.3390/genes11020131
Ahmad, B., Achek, A., Farooq, M. & Choi, S. Accelerated NLRP3 inflammasome-inhibitory peptide design using a recurrent neural network model and molecular dynamics simulations. Comput Struct. Biotechnol. J. 21, 4825–4835 (2023).
pubmed: 37854633
pmcid: 10579963
doi: 10.1016/j.csbj.2023.09.038
Bai, R. et al. The role of NLRP3 inflammasome in cerebrovascular diseases pathology and possible therapeutic targets. ASN Neuro 13, 17590914211018100 (2021).
pubmed: 34053242
pmcid: 8168029
doi: 10.1177/17590914211018100
Wu, K. K. L. et al. The APPL1-Rab5 axis restricts NLRP3 inflammasome activation through early endosomal-dependent mitophagy in macrophages. Nat. Commun. 12, 6637 (2021).
pubmed: 34789781
pmcid: 8599493
doi: 10.1038/s41467-021-26987-1
Ravaut, G., Légiot, A., Bergeron, K.-F. & Mounier, C. Monounsaturated fatty acids in obesity-related inflammation. Int. J. Mol. Sci. 22, 330 (2020).
pubmed: 33396940
pmcid: 7795523
doi: 10.3390/ijms22010330
Giordano, A. et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J. Lipid Res. 54, 2423–2436 (2013).
pubmed: 23836106
pmcid: 3735940
doi: 10.1194/jlr.M038638
Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914–920 (2009).
pubmed: 19633658
doi: 10.1038/nm.1964
Wani, K., AlHarthi, H., Alghamdi, A., Sabico, S. & Al-Daghri, N. M. Role of NLRP3 inflammasome activation in obesity-mediated metabolic disorders. Int. J. Environ. Res. Public Health 18, 511 (2021).
pubmed: 33435142
pmcid: 7826517
doi: 10.3390/ijerph18020511
Swanson, K. V., Deng, M. & Ting, J. P.-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).
pubmed: 31036962
pmcid: 7807242
doi: 10.1038/s41577-019-0165-0
Kursawe, R. et al. A role of the inflammasome in the low storage capacity of the abdominal subcutaneous adipose tissue in obese adolescents. Diabetes 65, 610–618 (2016).
pubmed: 26718495
doi: 10.2337/db15-1478
Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).
pubmed: 21217695
pmcid: 3076025
doi: 10.1038/nm.2279
Saklayen, M. G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 20, 12 (2018).
pubmed: 29480368
pmcid: 5866840
doi: 10.1007/s11906-018-0812-z
Goossens, G. H. et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol. Immunol. 50, 142–149 (2012).
pubmed: 22325453
doi: 10.1016/j.molimm.2012.01.005
Xia, M. et al. Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. Am. J. Pathol. 184, 1617–1628 (2014).
pubmed: 24631027
pmcid: 4005976
doi: 10.1016/j.ajpath.2014.01.032
Legrand-Poels, S. et al. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Biochem Pharm. 92, 131–141 (2014).
pubmed: 25175736
doi: 10.1016/j.bcp.2014.08.013
Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408–415 (2011).
pubmed: 21478880
pmcid: 4090391
doi: 10.1038/ni.2022
Unamuno, X. et al. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol. Immunol. 18, 1045–1057 (2021).
pubmed: 31551515
doi: 10.1038/s41423-019-0296-z
Tang, Y., Fung, E., Xu, A. & Lan, H.-Y. C-reactive protein and ageing. Clin. Exp. Pharm. Physiol. 44, 9–14 (2017).
doi: 10.1111/1440-1681.12758
Finucane, O. M. et al. Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. Diabetes 64, 2116–2128 (2015).
pubmed: 25626736
doi: 10.2337/db14-1098
López-Reyes, A. et al. NLRP3 inflammasome: the stormy link between obesity and COVID-19. Front Immunol. 11, 570251 (2020).
pubmed: 33193349
pmcid: 7662564
doi: 10.3389/fimmu.2020.570251
Bhatraju, P. K. et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N. Engl. J. Med. 382, 2012–2022 (2020).
pubmed: 32227758
doi: 10.1056/NEJMoa2004500
Simonnet, A. et al. High prevalence of obesity in severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 28, 1195–1199 (2020).
pubmed: 32271993
doi: 10.1002/oby.22831
Diabetes. World Health Organization https://www.who.int/news-room/fact-sheets/detail/diabetes (2023).
Ahechu, P. et al. NLRP3 inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development. Front Immunol. 9, 2918 (2018).
pubmed: 30619282
pmcid: 6297839
doi: 10.3389/fimmu.2018.02918
Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930–939 (2009).
pubmed: 19633656
pmcid: 3115752
doi: 10.1038/nm.2002
Ziegler, A. N., Levison, S. W. & Wood, T. L. Insulin and IGF receptor signalling in neural-stem-cell homeostasis. Nat. Rev. Endocrinol. 11, 161–170 (2015).
pubmed: 25445849
doi: 10.1038/nrendo.2014.208
Jager, J., Grémeaux, T., Cormont, M., Le Marchand-Brustel, Y. & Tanti, J.-F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148, 241–251 (2007).
pubmed: 17038556
doi: 10.1210/en.2006-0692
Spranger, J. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52, 812–817 (2003).
pubmed: 12606524
doi: 10.2337/diabetes.52.3.812
Stienstra, R. et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. 108, 15324–15329 (2011).
pubmed: 21876127
pmcid: 3174591
doi: 10.1073/pnas.1100255108
Cardiovascular Disease: An Introduction. in Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems vol. 8 1–90 (Nature Publishing Group, 2018).
Cardiovascular diseases (CVDs). World Health Organization https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2021).
Krishnan, S. M., Sobey, C. G., Latz, E., Mansell, A. & Drummond, G. R. IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br. J. Pharm. 171, 5589–5602 (2014).
doi: 10.1111/bph.12876
Qi, J. et al. NF-κB blockade in hypothalamic paraventricular nucleus inhibits high-salt-induced hypertension through NLRP3 and Caspase-1. Cardiovasc. Toxicol. 16, 345–354 (2016).
pubmed: 26438340
doi: 10.1007/s12012-015-9344-9
Gan, W. et al. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys. Acta Mol. Basis Dis. 1864, 1–10 (2018).
pubmed: 28986310
doi: 10.1016/j.bbadis.2017.10.001
Su, Q. et al. Inhibition of reactive oxygen species in hypothalamic paraventricular nucleus attenuates the renin-angiotensin system and proinflammatory cytokines in hypertension. Toxicol. Appl. Pharm. 276, 115–120 (2014).
doi: 10.1016/j.taap.2014.02.002
Zhaolin, Z., Guohua, L., Shiyuan, W. & Zuo, W. Role of pyroptosis in cardiovascular disease. Cell Prolif. 52, e12563 (2019).
pubmed: 30525268
doi: 10.1111/cpr.12563
Hoseini, Z. et al. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. J. Cell Physiol. 233, 2116–2132 (2018).
pubmed: 28345767
doi: 10.1002/jcp.25930
Libby, P. et al. Atherosclerosis. Nat. Rev. Dis. Prim. 5, 56 (2019).
pubmed: 31420554
doi: 10.1038/s41572-019-0106-z
Garg, N. J. Inflammasomes in cardiovascular diseases. Am. J. Cardiovasc Dis. 1, 244–254 (2011).
pubmed: 22254202
pmcid: 3253520
Olsen, M. B. et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl. Sci. 7, 84–98 (2022).
pubmed: 35128212
doi: 10.1016/j.jacbts.2021.08.006
Peng, K. et al. P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation. Int. J. Mol. Med. 35, 1179–1188 (2015).
pubmed: 25761252
pmcid: 4380202
doi: 10.3892/ijmm.2015.2129
Usui, F. et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem Biophys. Res. Commun. 425, 162–168 (2012).
pubmed: 22819845
doi: 10.1016/j.bbrc.2012.07.058
Abderrazak, A. et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation 131, 1061–1070 (2015).
pubmed: 25613820
doi: 10.1161/CIRCULATIONAHA.114.013730
Jhang, J.-J. & Yen, G.-C. The role of Nrf2 in NLRP3 inflammasome activation. Cell Mol. Immunol. 14, 1011–1012 (2017).
pubmed: 29129911
pmcid: 5719138
doi: 10.1038/cmi.2017.114
Chen, M., Masaki, T. & Sawamura, T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharm. Ther. 95, 89–100 (2002).
doi: 10.1016/S0163-7258(02)00236-X
Ding, Z. et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc. Res. 103, 619–628 (2014).
pubmed: 24776598
pmcid: 4200051
doi: 10.1093/cvr/cvu114
Sandanger, Ø. et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 99, 164–174 (2013).
pubmed: 23580606
doi: 10.1093/cvr/cvt091
Li, L. et al. Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction. Basic Res. Cardiol. 110, 56 (2015).
pubmed: 26463597
doi: 10.1007/s00395-015-0515-4
Liu, D., Zeng, X., Li, X., Mehta, J. L. & Wang, X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res. Cardiol. 113, 5 (2018).
pubmed: 29224086
doi: 10.1007/s00395-017-0663-9
Wu, D. et al. NLRP3 (nucleotide oligomerization domain-like receptor family, pyrin domain containing 3)-caspase-1 inflammasome degrades contractile proteins: implications for aortic biomechanical dysfunction and aneurysm and dissection formation. Arterioscler Thromb. Vasc. Biol. 37, 694–706 (2017).
pubmed: 28153878
pmcid: 5364046
doi: 10.1161/ATVBAHA.116.307648
Divakaran, S. & Loscalzo, J. The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics. J. Am. Coll. Cardiol. 70, 2393–2410 (2017).
pubmed: 29096811
pmcid: 5687289
doi: 10.1016/j.jacc.2017.09.1064
Mao, K. et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 23, 201–212 (2013).
pubmed: 23318584
pmcid: 3567828
doi: 10.1038/cr.2013.6
Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol. Cancer 17, 57 (2018).
pubmed: 29455639
pmcid: 5817726
doi: 10.1186/s12943-018-0779-z
Weber, A. N. R. et al. Bruton’s Tyrosine Kinase: an emerging key player in innate immunity. Front Immunol. 8, 1454 (2017).
pubmed: 29167667
pmcid: 5682317
doi: 10.3389/fimmu.2017.01454
Murthy, P. et al. The NLRP3 inflammasome and bruton’s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. Biochem Biophys. Res. Commun. 483, 230–236 (2017).
pubmed: 28034752
doi: 10.1016/j.bbrc.2016.12.161
Qiao, J. et al. NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis. Haematologica 103, 1568–1576 (2018).
pubmed: 29794149
pmcid: 6119128
doi: 10.3324/haematol.2018.191700
Zhang, W. et al. Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation. PLoS One 9, e107639 (2014).
pubmed: 25216263
pmcid: 4162616
doi: 10.1371/journal.pone.0107639
Zeng, C. et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol. 34, 101523 (2020).
pubmed: 32273259
pmcid: 7327979
doi: 10.1016/j.redox.2020.101523
Audia, J. P. et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res. Cardiol. 113, 32 (2018).
pubmed: 29992382
pmcid: 6396295
doi: 10.1007/s00395-018-0692-z
Butts, B., Butler, J., Dunbar, S. B., Corwin, E. & Gary, R. A. Effects of exercise on ASC Methylation and IL-1 cytokines in heart failure. Med Sci. Sports Exerc. 50, 1757–1766 (2018).
pubmed: 29683921
pmcid: 6095733
doi: 10.1249/MSS.0000000000001641
Wang, Y. et al. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin. Transl. Med. 10, 91–106 (2020).
pubmed: 32508013
pmcid: 7240865
doi: 10.1002/ctm2.13
Chan, Y. et al. Introduction to chronic respiratory diseases: a pressing need for novel therapeutic approaches. in Medicinal Plants for Lung Diseases (eds. Dua, K. et al.) 47–84 (Springer, Singapore, 2021). https://doi.org/10.1007/978-981-33-6850-7_2 .
De Nardo, D., De Nardo, C. M. & Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am. J. Pathol. 184, 42–54 (2014).
pubmed: 24183846
pmcid: 3873477
doi: 10.1016/j.ajpath.2013.09.007
Broide, D. H. et al. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 89, 958–967 (1992).
pubmed: 1374772
doi: 10.1016/0091-6749(92)90218-Q
Konno, S. et al. Cytokine concentrations in sputum of asthmatic patients. Int. Arch. Allergy Immunol. 109, 73–78 (1996).
pubmed: 8527954
doi: 10.1159/000237234
Yang, W., Ni, H., Wang, H. & Gu, H. NLRP3 inflammasome is essential for the development of chronic obstructive pulmonary disease. Int. J. Clin. Exp. Pathol. 8, 13209–13216 (2015).
pubmed: 26722520
pmcid: 4680465
2020 Global Strategy for Prevention, Diagnosis and Management of COPD. Global Initiative for Chronic Obstructive Lung Disease - GOLD https://goldcopd.org/gold-reports/ (2020).
Yu, Y. et al. Th1/Th17 cytokine profiles are associated with disease severity and exacerbation frequency in COPD patients. Int. J. Chron. Obstruct Pulmon Dis. 15, 1287–1299 (2020).
pubmed: 32606639
pmcid: 7294048
doi: 10.2147/COPD.S252097
Wang, H. et al. NLRP3 inflammasome involves in the acute exacerbation of patients with chronic obstructive pulmonary disease. Inflammation 41, 1321–1333 (2018).
pubmed: 29656319
doi: 10.1007/s10753-018-0780-0
Nachmias, N. et al. NLRP3 inflammasome activity is upregulated in an in-vitro model of COPD exacerbation. PLoS One 14, e0214622 (2019).
pubmed: 31112544
pmcid: 6529002
doi: 10.1371/journal.pone.0214622
Zhang, M.-Y. et al. Cigarette smoke extract induces pyroptosis in human bronchial epithelial cells through the ROS/NLRP3/caspase-1 pathway. Life Sci. 269, 119090 (2021).
pubmed: 33465393
doi: 10.1016/j.lfs.2021.119090
Rodríguez-Alcázar, J. F. et al. Charcot-Leyden crystals activate the NLRP3 inflammasome and cause IL-1β inflammation in human macrophages. J. Immunol. 202, 550–558 (2019).
pubmed: 30559319
doi: 10.4049/jimmunol.1800107
Parfenova, O. K., Kukes, V. G. & Grishin, D. V. Follistatin-like proteins: structure, functions and biomedical importance. Biomedicines 9, 999 (2021).
pubmed: 34440203
pmcid: 8391210
doi: 10.3390/biomedicines9080999
Wang, Y. et al. FSTL1 aggravates OVA-induced inflammatory responses by activating the NLRP3/IL-1β signaling pathway in mice and macrophages. Inflamm. Res. 70, 777–787 (2021).
pubmed: 34076707
doi: 10.1007/s00011-021-01475-w
Tsai, Y.-M. et al. Der f1 induces pyroptosis in human bronchial epithelia via the NLRP3 inflammasome. Int. J. Mol. Med. 41, 757–764 (2018).
pubmed: 29207030
Wood, L. G. et al. Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. J. Allergy Clin. Immunol. 143, 305–315 (2019).
pubmed: 29857009
doi: 10.1016/j.jaci.2018.04.037
Guo, D., Shi, Z., Luo, Y., Ding, R. & He, P. Association between oral health behavior and chronic diseases among middle-aged and older adults in Beijing, China. BMC Oral. Health 23, 97 (2023).
pubmed: 36788510
pmcid: 9926674
doi: 10.1186/s12903-023-02764-y
Park, E. et al. Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection. Infect. Immun. 82, 112–123 (2014).
pubmed: 24126516
pmcid: 3911849
doi: 10.1128/IAI.00862-13
Chen, Y. et al. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation. Cell Prolif. 54, e12973 (2021).
pubmed: 33382502
doi: 10.1111/cpr.12973
Naglik, J. R., König, A., Hube, B. & Gaffen, S. L. Candida albicans-epithelial interactions and induction of mucosal innate immunity. Curr. Opin. Microbiol. 40, 104–112 (2017).
pubmed: 29156234
pmcid: 5733685
doi: 10.1016/j.mib.2017.10.030
Pizzicannella, J. et al. Antioxidant ascorbic acid modulates NLRP3 inflammasome in LPS-G treated oral stem cells through NFκB/Caspase-1/IL-1β pathway. Antioxidants (Basel) 10, 797 (2021).
pubmed: 34069836
doi: 10.3390/antiox10050797
Yamaguchi, N. H. Smoking, immunity, and DNA damage. Transl. Lung Cancer Res. 8, S3–S6 (2019).
pubmed: 31211100
pmcid: 6546629
doi: 10.21037/tlcr.2019.03.02
Osman, M. & Papon, N. Smoking-aggravated oral candidiasis: Nrf2 pathway dampens NLRP3 inflammasome. J. Cell Mol. Med. 25, 9473–9475 (2021).
pubmed: 34486221
pmcid: 8500950
doi: 10.1111/jcmm.16901
Villani, A.-C. et al. Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat. Genet 41, 71–76 (2009).
pubmed: 19098911
doi: 10.1038/ng.285
Kastbom, A. et al. Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology 47, 415–417 (2008).
pubmed: 18263599
doi: 10.1093/rheumatology/kem372
Pontillo, A. et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 45, 271–278 (2012).
pubmed: 22235789
doi: 10.3109/08916934.2011.637532
Hitomi, Y. et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J. Allergy Clin. Immunol. 124, 779–785.e6 (2009).
pubmed: 19767079
doi: 10.1016/j.jaci.2009.07.044
Pontillo, A. et al. A 3’UTR SNP in NLRP3 gene is associated with susceptibility to HIV-1 infection. J. Acquir Immune Defic. Syndr. 54, 236–240 (2010).
pubmed: 20502346
doi: 10.1097/QAI.0b013e3181dd17d4
Pontillo, A. et al. Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 43, 583–589 (2010).
pubmed: 20370570
doi: 10.3109/08916930903540432
Caseley, E. A. et al. An atypical autoinflammatory disease due to an LRR domain NLRP3 mutation enhancing binding to NEK7. J. Clin. Immunol. 42, 158–170 (2022).
pubmed: 34671876
doi: 10.1007/s10875-021-01161-w
Jesus, A. A. et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIAS1 missense mutation. J. Clin. Immunol. 28, 134–138 (2008).
pubmed: 18080732
doi: 10.1007/s10875-007-9150-7
Zheng, Y. et al. Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes. Gene 530, 151–154 (2013).
pubmed: 23973727
doi: 10.1016/j.gene.2013.07.082
Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037–1046 (2017).
pubmed: 28167322
pmcid: 6536116
doi: 10.1016/j.jhep.2017.01.022
Csak, T. et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54, 133–144 (2011).
pubmed: 21488066
doi: 10.1002/hep.24341
Zheng, M. et al. Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. J. Biol. Chem. 295, 14040–14052 (2020).
pubmed: 32763970
pmcid: 7549031
doi: 10.1074/jbc.RA120.015036
Pirzada, R. H., Ahmad, B., Qayyum, N. & Choi, S. Modeling structure–activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics. Front. Endocrinol. 14, 1084327 (2023).
doi: 10.3389/fendo.2023.1084327
Fung, S.-Y., Yuen, K.-S., Ye, Z.-W., Chan, C.-P. & Jin, D.-Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg. Microbes Infect. 9, 558–570 (2020).
pubmed: 32172672
pmcid: 7103735
doi: 10.1080/22221751.2020.1736644
Bonomini, F., Dos Santos, M., Veronese, F. V. & Rezzani, R. NLRP3 inflammasome modulation by melatonin supplementation in chronic pristane-induced lupus nephritis. Int. J. Mol. Sci. 20, 3466 (2019).
pubmed: 31311094
pmcid: 6678949
doi: 10.3390/ijms20143466
Wu, X. et al. Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 axis. Oxid. Med. Cell Longev. 2019, 4087298 (2019).
pubmed: 30755784
pmcid: 6348879
Triantafilou, K., Hughes, T. R., Triantafilou, M. & Morgan, B. P. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 126, 2903–2913 (2013).
pubmed: 23613465
de Rivero Vaccari, J. P. et al. P2X4 receptors influence inflammasome activation after spinal cord injury. J. Neurosci. 32, 3058–3066 (2012).
pubmed: 22378878
pmcid: 6622016
doi: 10.1523/JNEUROSCI.4930-11.2012
Yang, F. et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J. Cereb. Blood Flow. Metab. 34, 660–667 (2014).
pubmed: 24424382
pmcid: 3982086
doi: 10.1038/jcbfm.2013.242
Ruscitti, P. et al. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin. Exp. Immunol. 182, 35–44 (2015).
pubmed: 26095630
pmcid: 4578506
doi: 10.1111/cei.12667
Li, F. et al. Pretreatment of indobufen and aspirin and their combinations with clopidogrel or ticagrelor alleviates inflammasome mediated pyroptosis via inhibiting NF-κB/NLRP3 pathway in ischemic stroke. J. Neuroimmune Pharm. 16, 835–853 (2021).
doi: 10.1007/s11481-020-09978-9
Choi, S. & Rather, B. A. Nlrp3 inflammasome inhibitory peptide for treatment of inflammatory diseases. (2022).
Klughammer, B. et al. A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin. Transl. Med. 13, e1471 (2023).
pubmed: 37962000
pmcid: 10644327
doi: 10.1002/ctm2.1471
Bakhshi, S. & Shamsi, S. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: latest evidence and therapeutic outcomes. Int. Immunopharmacol. 106, 108595 (2022).
pubmed: 35124417
doi: 10.1016/j.intimp.2022.108595
Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 588–606 (2018).
pubmed: 30026524
doi: 10.1038/nrd.2018.97
Nelson, B. E. et al. First in human phase I study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors. JCO 41, e14584–e14584 (2023).
doi: 10.1200/JCO.2023.41.16_suppl.e14584